Blood Res.  2014 Mar;49(1):72-73. 10.5045/br.2014.49.1.72.

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload

• Alavi S
• Sadeghi E
• Ashenagar

• KMID: 2172829
• DOI: http://doi.org/10.5045/br.2014.49.1.72

Abstract

No abstract available.

MeSH Terms

beta-Thalassemia*
Chelation Therapy*
Humans
Iron Overload*
Iron*
Iron

Reference

1. Belhoul KM, Bakir ML, Kadhim AM, Dewedar HE, Eldin MS, Alkhaja FA. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre. Ann Saudi Med. 2013; 33:18–21. PMID: 23458935.

2. Kwiatkowski JL. Management of transfusional iron overload differential - properties and efficacy of iron chelating agents. J Blood Med. 2011; 2:135–149. PMID: 22287873.

3. Chhim RF, Shelton CM, Christensen ML. Recent new drug approvals, part 2: drugs undergoing active clinical studies in children. J Pediatr Pharmacol Ther. 2013; 18:14–38. PMID: 23616733.

4. Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW. Combined iron chelation therapy. Ann N Y Acad Sci. 2010; 1202:79–86. PMID: 20712777.

5. Viprakasit V, Nuchprayoon I, Chuansumrit A, et al. Deferiprone (GPO-L-ONE(®)) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol. 2013; 88:251–260. PMID: 23460233.

6. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010; 148:466–475. PMID: 19912219.

7. Porter JB, Wood J, Olivieri N, et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson. 2013; 15:38. PMID: 23688265.

8. Pennell DJ. T2^* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci. 2005; 1054:373–378. PMID: 16339685.

9. Balocco M, Carrara P, Pinto V, Forni GL. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. Am J Hematol. 2010; 85:460–461. PMID: 20513129.

10. Voskaridou E, Christoulas D, Terpos E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol. 2011; 154:654–656. PMID: 21615376.